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Abstract  
Introduction 
 
Utilization of a bellyboard device reduces small bowel dose for patients receiving radiation therapy 
for rectal cancer. The reduction of small bowel dose with the bellyboard is even more significant 
in intensity modulated radiation therapy rectal treatments, as opposed to conventional 3D 
treatments.  However, there is evidence of increased setup variation with prone bellyboard 
positioning, especially in pitch and roll.  The purpose of this study is to determine the margin 
needed between the clinical target volume and the planning target volume to adequately account 
for these setup variations when planning volumetric modulated arc therapy rectal cases utilizing 
the bellyboard device.  The most preferable margin will provide the highest clinical target volume 
(CTV) dose coverage without significantly increasing normal tissue dose, as assessed through on-
treatment cone beam computed tomography imaging. 
 
Methods 
 
This study utilized retrospective data from seven rectal cancer patients that received radiotherapy 
treatment prone on a bellyboard device at a pair of Midwest Hospitals. Using computed 
tomography simulation data, three volumetric modulated arc therapy (VMAT) plans were created 
for each patient.  The three treatment plans differ in the amount of margin added to the CTV to 
create the planning target volume (PTV). A 0.5cm margin was used in the superior-inferior 
direction and the anterior-posterior margin will vary between the three plans (0.5, 0.8, and 1.0 cm).  
Varian Eclipse image registration software was used to calculate the dose a patient would have 
received based on cone beam computed tomography imaging.  The appropriate CTV-to-PTV 
margin was determined by comparing the dose delivered to the CTV and normal structures.  
 
Results 
 
Variations in pitch were a significant predictor of differences in CTV coverage between the three 
plans (p < .0001, χ2 = 55.5).  Between the 0.5 cm and 0.8 cm plans: CTV 98% increased by 0.97% 
(95% CI 0.73-1.22%, p <.0001).  Bowel V45Gy increased by 4.82 cc (95% CI 3.13-6.52 cc, p 
<.0001).  Bladder V40Gy increased by 4.79 cc (95% CI 3.55-6.03 cc, p <.0001).  Between the 0.5 
cm and 1.0 cm plans: CTV 98% increased by 1.41% (95% CI 1.04-1.77%, p <.0001).  Bowel 
V45Gy increased by 8.91 cc (95% CI 5.25-12.56 cc, p <.0001).  Bladder V40Gy increased by 9.90 
cc (95% CI 7.54-12.27 cc, p <.0001).   
  
Conclusion 
 
Utilization of a 1.0 cm axial margin leads to a significant increase in CTV coverage by 98% of the 
prescription dose.  Corresponding increases in OAR doses are still within generally accepted 
tolerances and can be mitigated through proper use of bellyboard positioning, bladder filling and 
VMAT techniques. 
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Introduction  
 Colorectal cancer is the third-most prevalent cancer diagnosis in both men and women, 
following breast, prostate and lung cancer.  There were an estimated 101,420 new cases of 
colorectal cancer in 2019.  An estimated 44,180 of these individuals were diagnosed with rectal 
cancer.  Colorectal cancer is the third leading cause of cancer death for both men and women, 
accounting for an estimated 51,020 deaths in 20191.  Rectal cancers most commonly present as 
stage 2-3 and 5-year overall survival for these patients is approximately 65%2.  Locally advanced 
rectal cancer is treated using a multimodality approach of neoadjuvant chemoradiation, followed 
by surgical resection and adjuvant chemotherapy. 
 The rectum is located at the end of the gastrointestinal tract, just proximal to the anal canal.  
The rectum begins anterior to the sacrum around the 3rd sacral segment, and follows the curvature 
of the sacrum.  The rectum is typically 4 to 5 inches in length.  The upper third of the rectum and 
the anterior wall of the middle third is covered by serosa, while the lower third is covered only by 
a muscularis layer. The peritoneal reflection is the point where the serosa reflects superiorly to 
cover the upper portion of the rectum.  First station lymphatic drainage for the rectum includes the 
internal iliac and presacral lymph nodes, followed by the common and paraaortic nodes3. 
 Rectal cancer is associated with a diet high in fat and red meat and low in fiber.  Presenting 
symptoms often include rectal bleeding or changes in bowel habits.  The most common histological 
subtype in rectal cancer is adenocarcinoma.  Patterns of failure in rectal cancer are often 
determined by their location relative to the peritoneal reflection.  Tumors located above the 
peritoneal reflection have an increased likelihood of distant failure.  These tumors have the ability 
to penetrate the peritoneum and seed into the abdominal cavity.  Local recurrence is the most 
common method of failure for tumors located below the peritoneal reflection.  Without an outer 
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serosal layer, these lesions are much more likely to directly invade or adhere to adjacent organs in 
the pelvis4. 
 Surgical resection with total mesorectal excision is the primary treatment for cancers of the 
rectum.  This technique involves removal of an intact portion of the rectum along with surrounding 
mesorectal fatty lymphovascular tissue.  Excision of the entire mesorectal envelope results in lower 
postoperative morbidity and local recurrence, while improving long-term survival.  There are two 
main surgical approaches depending on the location of the primary tumor within the rectum.  If 
the tumor is located higher in the rectum an anterior resection or a low anterior resection (LAR) 
may be performed with a colo-anal anastomosis to salvage some normal bowel function.  A tumor 
located closer to the anus would necessitate an abdominoperineal resection (APR), in which the 
affected area of the rectum and the anus are removed, leaving the individual with a permanent end 
colostomy5.   
The National Comprehensive Cancer Network recommends combined modality treatment 
for T3 or T4 rectal cancer, as well as node-positive disease6.  A multi-modality approach has been 
shown to reduce the risk of local recurrence and the morbidity associated with salvage therapy 
after local recurrence.  This regimen consists of neo-adjuvant radiation therapy with concurrent 
chemotherapy, followed by surgery 6-8 weeks later with further adjuvant chemotherapy.  
Fluorouracil (5-FU) is the primary neo-adjuvant chemotherapy agent, a radiosensitizer used to 
enhance the effects of radiation treatment.  Newer chemotherapy regimens have replaced 5-FU 
with oral capecitabine with the aim of reducing small bowel toxicities.  The most commonly used 
fractionation scheme in the United States consists of 45 Gy to the clinical target volume with a 5.4 
Gy boost to the primary tumor and involved lymph nodes in 28 daily fractions7. 
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In 2010 Radiation Therapy Oncology Group (RTOG) established consensus guidelines for 
the delineation elective clinical target volumes (CTV) to be used for planning pelvic intensity-
modulated radiotherapy (IMRT) for rectal cancers.  For the majority of locally advanced rectal 
cancers the CTV consists of the internal iliac, pre-sacral and peri-rectal nodal groups. The CTV 
should extend no less than 2 cm below any gross disease or to the pelvic floor, whichever is lower.  
In the mid-pelvis, the CTV should extend to the pelvis sidewall musculature posterior and laterally.  
The anterior margin should include 1 cm of the posterior bladder, to account for day-to-day 
variation in bladder position.  The upper margin of the CTV should be where the common iliac 
vessels bifurcate into external/internal iliacs (approximately at the level of the sacral promontory), 
in order to ensure proper coverage of the internal iliac and pre-sacral nodal regions.  The CTV 
should extend posteriorly to within 1 cm of the sacrum to provide proper coverage of the pre-sacral 
region8. 
Organs at risk during radiation therapy for rectal cancer include the bladder, femoral heads 
and the small bowel.  Acute diarrhea is the most common side-effect of pelvic irradiation, and it 
is often compounded by the concurrent chemotherapy regimens used for rectal cancer.  Grade 3 
acute diarrhea can lead to failure to complete therapy and may be associated with the development 
of chronic diarrhea. The connection between high radiation doses (>45 Gy) and small bowel 
toxicities is well established, and more recent studies have also shown a link between the volume 
of small bowel receiving doses as low as 15 Gy and Grade 3 toxicities9. 
In order to minimize small bowel dose, it is important to move the small bowel out of the 
treatment fields as much as possible.  A simple and effective means of accomplishing this is 
through prone patient positioning and the use of a bellyboard device.  Small bowel is displaced 
anteriorly and superiorly by allowing the patient’s abdomen to protrude through a cutout in the 
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device.  Use of prone positioning with the bellyboard device in combination with a full bladder 
has been shown to reduce the volume of small bowel in the treatment fields by 70%10.  However, 
there is evidence that use of the bellyboard device results in decreased reproducibility of patient 
setup, especially in pitch and roll11.  These variations need to be accounted for when considering 
the use of highly conformal radiotherapy techniques such as IMRT or volumetric modulated arc 
therapy (VMAT). 
The utilization of IMRT as an alternative to 3D-conformal radiation therapy (3DCRT) has 
significantly increased over recent years12.  Historically, the standard was to use a 3-field 
technique, consisting of two wedged laterals and a posterior-anterior field.  This method provides 
excellent target coverage and well-tolerated toxicities.  However, the current focus on 
intensification of neo-adjuvant chemotherapy and the addition of novel radiosensitizers, has 
contributed to the desire to lower radiation induced toxicity rates even further13. 
Both IMRT and VMAT techniques have the ability to achieve higher tumor doses while 
sparing more normal tissue.  By reducing the volume of small bowel irradiated, these techniques 
have the potential to decrease gastrointestinal (GI) toxicities in the treatment of locally advanced 
rectal cancers. In several retrospective dosimetric comparison studies between IMRT and 3DCRT, 
small bowel sparing was significantly improved while target coverage and conformity was 
maintained.  The volume of small bowel receiving 15 Gy was also reduced with IMRT treatment14-
17.   
Despite dosimetric advantages, there is conflicting evidence whether IMRT provides any 
clinical benefit to GI toxicity.  Several retrospective studies have shown IMRT to reduce GI 
toxicities and diarrhea when compared to 3DCRT18-20.  A pair of RTOG trials were used to 
compare the GI toxicity rates between patients treated with IMRT vs 3DCRT neo-adjuvant 
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radiation with concurrent capecitabine/oxaliplatin for locally advanced rectal cancer.  IMRT was 
unable to reduce the high rates of GI toxicity or diarrhea that are associated with oxaliplatin21.  
Furthermore, a nationwide retrospective analysis conducting using data from the National Cancer 
Database determined that IMRT did not improve perioperative outcomes or overall survival12. 
 Studies comparing VMAT treatment to 3DCRT have been more limited.  In two 
retrospective dosimetric studies the small bowel V15 was significantly lower for VMAT vs 
3DCRT14,17.  In another study, the small bowel V40 was reduced by 60% for patients receiving 
VMAT15.  The only study comparing GI toxicity between VMAT and 3DCRT reported a 41% 
downstaging rate with IMRT and comparable toxicity rates between the two groups22.  
 With the increasing use of IMRT techniques to treat locally advanced rectal cancer, the 
continued use of the bellyboard device has come into question. Recent research has shown that 
IMRT used in conjunction with the bellyboard device is the most effective means of reducing 
small bowel dose23.  The study’s author posits that similar results would have been found if they 
had utilized VMAT. 
 When highly conformal treatment techniques such as VMAT are used, any discrepancies 
in day-to-day patient setup can greatly affect dosimetric target coverage.  The variations created 
by use of the bellyboard device need to be adequately accounted for during the planning process.   
ICRU Report 83 states that the purpose of the PTV is “…to ensure that the prescribed 
absorbed dose will actually be delivered to all parts of the CTV with a clinically acceptable 
probability, despite geometrical uncertainties such as organ motion and setup variations.”  The 
report also reiterates the need for PTVs to be customized based on individual cancer sites, 
treatment techniques, and patient positioning factors24.  The problem of determining appropriate 
CTV to planning target volume margins has been investigated by various researchers. 
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Mathematical formulas have been developed to estimate the necessary CTV-PTV margin based 
on observed systematic and random errors25.  Post-treatment cone beam computed tomography 
(CBCT) images have been used to determine the degree of geometric miss when using standard 
CTV-to-PTV margins26.  Off-line image registration of cone beam computed tomography scans 
and planning computed tomography (CT) scans have also been used to determine setup variability 
and calculate appropriate margins27. 
 The purpose of this study is to determine the appropriate CTV-PTV margin needed to 
account for the variation in patient setup using the bellyboard device.  Multiple VMAT plans will 
be created to determine if varying the CTV-PTV margin has a significant effect on the total dose 
delivered to the CTV over the course of treatment based on setup variations observed on CBCTs.  
If any margin significantly improves the CTV dose coverage, further analysis will be performed 
to determine the most optimal margin.  Any change in small bowel dose between the margins will 
have to be weighed against the perceived clinical significance of the increased dose to the CTV. 
 
Methodology 
Patient Selection 
 This study is a retrospective dosimetric analysis of 7 patients with locally advanced rectal 
cancer that had been previously treated with radiation therapy utilizing the bellyboard device.  The 
subjects were treated at a pair of Midwest Hospitals and their data was obtained via a shared 
electronic medical record system.  All of the subjects were originally treated with a traditional 3-
field wedged pelvis technique while positioned prone on a bellyboard device.  In order to be 
included in the study, subjects needed to be over 18 years of age, diagnosed with locally advanced 
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rectal cancer and previously received radiation therapy whilst positioned prone on a bellyboard 
device.   
Most often 3D-conformal rectal treatments use on-board planar imaging to confirm patient 
positioning, mainly relegating CBCTs to the assessment of bladder filling.  As such, the number 
of study participants was limited by the availability of subjects who fit the criteria and also had a 
sufficient number of pre-treatment CBCTs available to represent patient positioning throughout 
the course of treatment.  For each subject in the study, the number of available CBCTs varied from 
5 to 20.  To homogenize the data, six CBCTs were utilized for each patient, with the exception of 
one subject who only had five available.  The six CBCTs were randomly selected from the total 
available for each subject.  If a subject had multiple CBCTs from a given treatment day, only the 
final pre-treatment CBCT was considered for use in the study. 
Institutional Review Board 
 The study was approved by the institutional review boards (IRB) of both Midwest Hospitals 
from which patient data was obtained and by the Grand Valley State University IRB.  Informed 
consent was waived by the review boards due to the retrospective nature of the study and the 
minimal risks to patient privacy.  The IRB protocols outline the measures taken to safeguard patient 
privacy in accordance with the Health Insurance Portability and Accountability Act of 1996.   
The Varian Eclipse treatment planning system (TPS) was used to strip data sets of any 
protected health information and export them to an external system folder on the hospital shared 
drive.  The anonymized copies of subjects’ CT simulation and CBCT data sets were then imported 
back into Eclipse and stored in the electronic medical records of temporary “anonymous” patients.  
The external folder was deleted after all data sets were imported.  All “anonymous” patient records, 
and data sets contained therein, were erased at the conclusion of the study. 
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Simulation 
Simulation protocol was similar at both Midwest Hospitals.  Each patient underwent a CT 
simulation in the prone position on the CIVCO carbon fiber bellyboard device (Figure 1).  The 
subjects were marked with three tattoos to aid in setup, two lateral marks and one posterior mark.  
A scale on the side of the CIVCO bellyboard allows for reproducible positioning of the patient 
relative to the device.  Depending on physician preference, some patients were administered oral 
contrast in order to better visualize the small bowel and rectum on the planning CT.  One site used 
a Siemens SOMATOM CT scanner and the other utilized a Philips Big Bore CT scanner. 
Planning 
   All of the patients involved in this study originally received external beam irradiation 
using a 3D-conformal technique consisting of one posterior-anterior field and two wedged laterals.  
When using 3D-conformal techniques, it is not necessary to contour nodes to be included in a 
clinical target volume (CTV), because field margins are determined by bony landmarks.  However, 
as this study seeks to evaluate target margins for VMAT techniques, it was necessary to create 
CTVs for each of the subjects.  The CTVs were contoured in accordance with the RTOG consensus 
guidelines mentioned previously8.  The principle investigator created the CTV contours and they 
were approved by a board-certified radiation oncologist.  
Contouring and planning was done using the Varian Eclipse TPS (v.15.6).  Bladder and 
small bowel were contoured in order to provide dose information on these critical structures.  On 
the CT simulation images, each loop of small bowel was contoured individually, with oral contrast 
(if present) contoured and assigned the density of air.   
The standard for VMAT rectal cases is a symmetrical 0.5 cm CTV-PTV margin21.  Since 
pitch and roll are the major causes of setup discrepancy when using the bellyboard11, the margins 
utilized in the comparison plans differ only in the radial dimensions.  Three plans were created for 
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each patient.  The first plan had symmetrical 0.5 cm CTV-PTV margins.  The second had 0.8 cm 
margins radially and 0.5 cm margins craniocaudally.  The third plan had 1.0 cm margins radially 
and 0.5 cm margins craniocaudally (Figure 2). 
VMAT plans with two partial, posterior arcs were used to reduce small bowel and bladder 
dose.  All plans were required to meet the coverage guidelines established in RTOG 082221.  
Coverage of >98% of the PTV with 95% of the prescribed dose, with <10% receiving 105% and 
<5% receiving 110% of the prescribed dose. Small bowel dose was limited to V35 <180 cc, V40 
<100 cc, and V45 <65 cc.  Bladder dose was limited to V40 <40%, V45 <15%, and a maximum 
dose 50 Gy.   
The same planner created each plan in the study to exclude any confounding variance 
introduced by planner specific skill or technique.  The nature of the VMAT optimization process 
makes the creation of identical plans with different PTVs impossible, but measures were taken to 
ensure adequate similarity for the sake of comparison.  After the baseline 0.5 cm CTV-PTV margin 
plan was created for each patient, optimization objectives were altered as little as possible besides 
changing the PTV.  Special effort was made to keep the dose to 98% of the PTV consistent between 
the three plans.  All plans were generated for the Varian Clinac iX linear accelerator with 6 MV 
photons.   
Dose Calculation 
To assess the ability of the different margins to account for setup variability, dose 
calculations were performed on CBCT images for each of the three plans.  In order for dose-
volume metrics to accurately reflect a subject’s position on a given treatment day, bowel and 
bladder contours were redrawn on each CBCT used in the study.  Although the small bowel 
contour was used for planning purposes, a bowel structure that included both colon and small 
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bowel was used for dose comparison with pre-treatment CBCTs.  This was necessary as colon and 
small bowel can be indistinguishable on lower quality CBCT images, which often contain more 
image artifacts. 
In order to create the CTV contours on each CBCT, a rigid auto-registration was performed 
between the CT simulation and CBCT images, based on the position of the patient’s sacrum.  The 
CTV contour was then copied onto the CBCT.  This process kept the CTV shape and size 
unchanged while adjusting the pitch, yaw and roll to match the treatment position.  The quality of 
each registration was assessed individually by two separate planners.  Degrees of pitch, yaw and 
roll discrepancy between initial CT simulation and each pre-treatment CBCT were recorded. 
The three plans for each subject were then copied onto each daily CBCT and dose was 
calculated on these image sets utilizing Varian’s Anisotropic Analytical Algorithm (AAA) (Figure 
3).  The Hounsfield Unit (HU) to density calibration curve for CBCTs is highly variable based on 
patient anatomy, therefore the derived dose-volume metrics are not absolute and are used only to 
create relative comparisons between the three plans on a given pretreatment CBCT.  Comparison 
of CTV coverage is the primary means of assessing the different planning margins, but OAR 
metrics are also important when evaluating the clinical impacts of increased margins.  For each 
subject, three dose-volume metrics were recorded for each plan on each pretreatment CBCT: 
percent volume of CTV receiving 98% of the prescription dose (CTV V98%[%]), absolute volume 
(cubic centimeters) of bowel receiving 45 Gy (Bowel V45Gy[cc]), and absolute volume (cc) of 
bladder receiving 40 Gy (Bladder V40Gy[cc]). 
Statistical Analysis 
Statistical analysis was performed using the GENMOD procedure in IBM SAS v.9.4.  A 
repeated measure Analysis of Variance (ANOVA) test with covariates was performed.  The 
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repeated measure is each subject’s individual pretreatment CBCT.  The covariates are the three 
measures of setup discrepancy: pitch, yaw and roll.  The test was performed separately for each 
output dose-volume metric: CTV V98%[%], Bowel V45Gy[cc] and Bladder V40Gy[cc].  
Comparisons of generalized estimating equation (GEE) parameters and their 95% confidence 
intervals (CI) were used to compare the differences between the three plans for a given dose metric, 
with a p < .05 indicating a significant difference.  Wald statistics were calculated for each of the 
covariates, with p < .05 indicating that changes in that covariate (pitch, yaw or roll) significantly 
impacted the variance in the dose metric between the three plans. 
 
Results 
The goal of this study is to evaluate the effects of three different axial CTV-PTV margins 
on target coverage when using VMAT to treat rectal cancer prone on a belly board device.  The 
data of seven previously treated rectal cancer patients was used to perform this analysis. 
Setup Variation 
 Setup variations were recorded for each of the pretreatment CBCTs analyzed in this study.  
The setup variations were quantified as degrees of difference between the original CT simulations 
and pretreatment CBCTs in three rotational axes: pitch, yaw and roll.  The Eclipse TPS rigid 
autoregistration software was used to register the images based on sacrum and pelvis position.  
 The average daily setup variation (degrees) for each patient can be seen in Table 1. The 
average daily setup variation across all patients was 2.86, 0.95 and 1.36 degrees for pitch, yaw and 
roll, respectively.  The greatest variation was seen in pitch with a minimum value of 0.0 degrees 
and a maximum of 7.6 degrees.  There was less variation in roll with a minimum value of 0.0 and 
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a maximum of 4.1 degrees.  Yaw showed the least variation with a minimum value of 0.0 degrees 
and maximum of 2.1 degrees (Figure 4). 
CTV Coverage 
 The CTV volumes for each patient ranged from 500.0 cc to 905.0 cc, with a mean volume 
of 721.6 cc across all subjects. Percent volume of CTV receiving 98% of the prescription dose 
(CTV V98%[%]) was used to evaluate the extent of coverage across the three plans (0.5, 0.8 and 
1.0 cm axial CTV-PTV margins).  This metric was measured by calculating and averaging the 
dose using pretreatment CBCT imaging.  The average CTV V98%[%] for each plan can be seen 
in Table 2.  The average difference in CTV V98% between the 0.8 and 0.5 cm plans, across all 
subjects, was 1.08%. The average difference in CTV V98% between the 1.0 and 0.5 cm plans, 
across all subjects, was 1.52% (Figure 8). 
Statistical analysis was performed using the GENMOD procedure in IBM SAS v.9.4.  A 
repeated measure Analysis of Variance (ANOVA) test with covariates was performed.  Wald 
statistics for the GEE analysis indicated that pitch significantly affected the difference in CTV 
coverage between the three plans, p < .0001, χ2 = 55.5 (Figure 5).  Neither yaw nor roll had a 
significant effect on CTV coverage between the plans, p = 0.73 and p = 0.93, respectively (Figures 
6 and 7). 
Analysis of GEE parameters provided estimates of the difference in CTV coverage between 
the three margins if they were utilized in the general population.  Between the 0.5 cm and 0.8 cm 
plans, it was estimated that there would be a 0.97% increase in CTV V98%, SE 0.125, 95% CI 
0.73-1.22%.  This indicated a significant difference in CTV V98% between 0.5 cm and 0.8 cm 
plans, Z = 7.42, p < .0001.  Between the 0.5 cm and 1.0 cm plans, it was estimated that there would 
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be a 1.41% increase in CTV V98%, SE 0.187, 95% CI 1.04-1.77%.  This indicated a significant 
difference in CTV V98% between 0.5 cm and 1.0 cm plans, Z = 6.99, p < .0001. 
Bowel Dose 
The bowel volumes for each patient ranged from 685.58 cc to 2141.02 cc at time of CT 
simulation, with a mean volume of 1288.72 cc across all subjects. The volume of bowel (cc) 
receiving at least 45 Gy (Bowel V45Gy[cc]), was used to evaluate the bowel dose across the three 
plans (0.5, 0.8 and 1.0 cm axial CTV-PTV margins).  This metric was measured by calculating the 
dose using pretreatment CBCT imaging.  The average Bowel V45Gy[cc] for each plan can be seen 
in Table 3.  The average difference in Bowel V45Gy between the 0.8 and 0.5 cm plans, across all 
subjects, was 3.15 cc.  The average difference in Bowel V45Gy between the 1.0 and 0.5 cm plans, 
across all subjects, was 5.17 cc. 
In the population, between the 0.5 cm and 0.8 cm plans, it was estimated that there would 
be a 4.82 cc increase in Bowel V45Gy, SE 0.86, 95% CI 3.13-6.52 cc.  This indicated a significant 
difference in Bowel V45Gy between 0.5 cm and 0.8 cm plans, Z = 5.59, p < .0001.  Between the 
0.5 cm and 1.0 cm plans, it was estimated that there would be an 8.91 cc increase in Bowel V45Gy, 
SE 1.86, 95% CI 5.25-12.56 cc.  This indicated a significant difference in Bowel V45Gy between 
0.5 cm and 1.0 cm plans, Z = 4.78, p < .0001. 
Bladder Dose 
The bladder volumes for each patient ranged from 54.26 cc to 285.04 cc at time of 
simulation, with a mean volume of 145.35 cc across all subjects. The volume of bladder (cc) 
receiving at least 40 Gy (Bladder V40Gy[cc]), was used to evaluate the bladder dose across the 
three plans (0.5, 0.8 and 1.0 cm axial CTV-PTV margins).  This metric was measured by 
calculating the dose using pretreatment CBCT imaging.  The average Bladder V40Gy[cc] for each 
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plan can be seen in Table 4.  The average difference in Bladder V40Gy between the 0.8 and 0.5 
cm plans, across all subjects, was 4.96 cc.  The average difference in Bladder V40Gy between the 
1.0 and 0.5 cm plans, across all subjects, was 10.12 cc. 
In the population, between the 0.5 cm and 0.8 cm plans, it was estimated that there would 
be a 4.79 cc increase in Bladder V40Gy, SE 0.63, 95% CI 3.55-6.03 cc.  This indicated a significant 
difference in Bladder V40Gy between 0.5 cm and 0.8 cm plans, Z = 7.59, p < .0001.  Between the 
0.5 cm and 1.0 cm plans, it was estimated that there would be a 9.90 cc increase in Bladder V40Gy, 
SE 1.21, 95% CI 7.54-12.27 cc.  This indicated a significant difference in Bladder V40Gy between 
0.5 cm and 1.0 cm plans, Z = 8.22, p < .0001. 
 
Discussion 
 The purpose of this study was to evaluate the ability of different CTV-PTV margins to 
account for the increased setup variability when using the prone bellyboard position to treat rectal 
cancer.  The results of this study indicated a statistically significant difference in CTV V98% 
coverage between the three plans evaluated, with a correspondingly significant increase in OAR 
doses.  Closer consideration is necessary to determine whether or not the magnitude of these 
differences would have any clinical impact. 
CTV Coverage 
 Utilization of the 1.0 cm margin lead to a 1.4% increase in CTV 98%, indicating a greater 
homogeneity of dose throughout the CTV.  Greater homogeneity of dose throughout the target 
volume has been shown to increase tumor control probability28.  However, some propose using 
less conservative coverage constraints dictating CTV coverage of 99% of the target volume by 
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95% of the prescription dose29.  All three of the plans and their accompanying margins were able 
to account for setup variation within this tolerance.    
Bowel & Bladder Doses  
RTOG 0822 recommends keeping Bowel V45Gy dose under 65 cc21.  The difference 
between the 0.5 and 1.0 cm plans was an increase of Bowel V45Gy of 5.25-12.56 cc.  Even with 
this increase in dose, well designed VMAT plans with 1.0 cm axial margins can keep the bowel 
dose below RTOG 0822 tolerances. 
 Bladder doses increased correspondingly between the 0.5 and 1.0 cm plans, with an 
increase of Bladder V40Gy of 3.55-6.03 cc.  RTOG recommends keeping Bladder V40Gy under 
40%21.  Bladder constraints could limit the use of 1.0 cm axial margins if the patient has 
particularly poor bladder filling.  In these cases, the 1.0 cm axial margin can be cropped out of the 
bladder by 0.2 to 0.5 cm to maintain the benefits in CTV coverage at the superior and inferior ends 
of the target volume while reducing bladder dose.  
Limitations 
 The length of CBCT scans limits the accuracy of dose calculations at the superior and 
inferior ends.  Even though the CTV was contained within the scan length in all of these cases, the 
lack of lateral scatter near the edges of the scan volume resulted in lower calculated dose to these 
areas.  While this effect was the same for each scan across the three plans of different margins, the 
area where the effect of pitch and yaw would be most pronounced is near the ends of the CTV.  
The lack of dose calculation accuracy in these areas might have led to an underestimation of the 
effects of the larger margins on CTV coverage.  
 The nature of inverse planning makes it impossible to create VMAT plans in the Eclipse 
TPS that are exactly alike with the exception of CTV-PTV margin.  The initial symmetrical 0.5 
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cm margin plan was created first, and every effort was made to keep the subsequent plans as alike 
as possible.  However, within the plan optimizer, the MLC sequence was out of the planner’s 
control, creating variation in the three plans beyond what would be seen if the margins were 
changed in a simple 3DCRT plan.  
 
Conclusion 
  External beam radiation for the treatment of rectal cancer has the potential to induce small 
bowel toxicity9.  Treating rectal cancer patients prone on a bellyboard device reduces small bowel 
doses10.  However, utilization of the bellyboard device increases daily setup variability11.  VMAT 
techniques further decrease small bowel doses, but allow less room for error in patient setup23.  
PTVs utilized in VMAT plans need to adequately account for any increased setup variations when 
using the bellyboard device. 
 This study evaluated three different plans with varying CTV-PTV margins.  The first with 
symmetrical 0.5 margins, the second with 0.5 craniocaudal margins and 0.8 cm axial margins and 
the third with 0.5 cm craniocaudal margins and 1.0 cm axial margins.  Compared to the 0.5 cm 
axial margin, the 1.0 cm axial margin resulted in a statistically significant increase in the CTV 
V98% by 1.04-1.77%.  Bowel V45Gy and Bladder V40Gy were also increased by 5.25-12.56 cc 
and 7.54-12.27 cc, respectively.  These results indicate that if the goal is greater prescription dose 
coverage of the CTV, 1.0 cm margins can be used with minimal increase in OAR volumes 
receiving near prescription doses. 
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Table 1. Average Daily Setup Variations Across Pretreatment CBCTs by 
Subject With Standard Deviation 
Subject Pitch (deg) 
Mean (SD) 
Yaw (deg) 
Mean (SD) 
Roll (deg) 
Mean (SD) 
1 3.65 (1.96) 0.97 (0.43) 1.08 (0.82) 
2 4.45 (1.34) 0.72 (0.67) 0.42 (0.45) 
3 5.28 (2.13) 0.67 (0.43) 1.07 (0.71) 
4a 0.42 (0.37) 0.96 (0.45) 0.86 (0.73) 
5 1.28 (0.83) 1.34 (0.59) 0.52 (0.32) 
6 3.10 (0.90) 1.17 (0.48) 3.52 (0.52) 
7 1.13 (0.68) 0.92 (0.83) 1.83 (0.58) 
Total 2.86 (2.05) 0.95 (0.57) 1.36 (1.18) 
 aOnly 5 pretreatment CBCTs were available for this subject. 
 
 
 
Table 2. Average CTV V98%[%] Across CBCTs for Each Plan by Subject 
With Standard Deviation 
Subject 0.5 cm Plan 0.8 cm Plan 1.0 cm Plan 
1 95.55 (1.96) 96.17 (1.85) 96.72 (1.74) 
2 97.42 (1.23) 98.08 (0.97) 98.30 (0.85) 
3 94.32 (1.72) 95.23 (1.40) 96.00 (1.19) 
4 98.19 (0.95) 99.45 (0.37) 99.59 (0.34) 
5 98.18 (0.95) 98.77 (0.56) 98.86 (0.44) 
6 96.72 (0.81) 98.56 (0.59) 98.84 (0.33) 
7 97.11 (2.04) 98.35 (1.31) 99.46 (0.50) 
Total 96.78 (1.42) 97.80 (1.52) 98.25 (1.37) 
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Table 3. Average Bowel V45Gy[cc] Across CBCTs for Each Plan by Subject 
With Standard Deviation 
Subject 0.5 cm Plan 0.8 cm Plan 1.0 cm Plan 
1 23.47 (4.35) 26.65 (3.19) 29.66 (3.30) 
2 320.98 (28.64) 339.89 (31.22) 358.90 (32.71) 
3 8.76 (5.03) 10.63 (5.88) 13.64 (6.63) 
4 92.44 (19.30) 96.33 (20.01) 95.34 (19.61) 
5 53.83 (8.04) 56.84 (8.03) 58.31 (8.20) 
6 50.67 (10.87) 54.84 (12.35) 53.17 (11.55) 
7 42.12 (22.18) 44.92 (23.92) 49.52 (26.93) 
Total 84.61 (107.49) 90.01 (113.41) 94.08 (119.51) 
 
 
 
Table 4. Average Bladder V40Gy[cc] Across CBCTs for Each Plan by Subject 
With Standard Deviation 
Subject 0.5 cm Plan 0.8 cm Plan 1.0 cm Plan 
1 13.33 (6.52) 17.28 (8.35) 20.97 (9.51) 
2 6.36 (2.30) 10.45 (1.97) 14.14 (2.44) 
3 9.42 (8.12) 12.02 (10.67) 15.78 (13.91) 
4 15.58 (6.36) 20.53 (7.04) 26.10 (7.48) 
5 10.74 (8.16) 16.48 (9.92) 20.18 (11.00) 
6 29.10 (12.56) 34.31 (14.02) 42.17 (15.23) 
7 70.69 (40.88) 82.97 (45.83) 94.38 (50.11) 
Total 22.17 (22.61) 27.72 (25.59) 33.39 (28.46) 
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Figure 1. CIVCO Carbon Fiber Bellyboard 
 
CIVCO Radiotherapy. http://civcort.com/ro/hip-pelvic-positioning/bellyboards 
 
   
Figure 2. Depiction of the Three Different PTV margins in Eclipse TPS 
 
 
Cyan = CTV, Yellow = PTV 0.5cm, Orange = PTV 0.8cm, Red = PTV 1.0cm 
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Figure 3. Comparison of Two Plans for a Subject Calculated on Simulation Data Set and  
CBCT Data Set 
 
 
Plan 0.5cm (Left) & Plan 1.0cm (Right), Simulation Data Set 
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Figure 4. Boxplot of Degrees of Variation by Rotational Direction 
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Figure 5. Predictive Value of Pitch on CTV V98%[%] (p < .0001). 
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Figure 6. Predictive Value of Yaw on CTV V98%[%] (p = 0.73). 
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Figure 7. Predictive Value of Roll on CTV V98%[%] (p = 0.93). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predicted Value
94
95
96
97
98
99
100
Roll
0.0 1.0 2.0 3.0 4.0 5.0
plan Plan0.5 Plan0.8 Plan1.0
 30 
Figure 8. Boxplot of CTV V98%[%] by Plan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
